App-Quantinova.ai

T-DM1 in HER2-negative metastatic breast cancer patients with HER2-amplified circulating tumor cells: Current status of the CirCe T-DM1 phase II trial

Bidard F-C - San Antonio Breast Cancer Symposium (SABCS) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Trastuzumab emtansine

Enumeration of heterogeneous circulating tumor cells (CTCs) in metastatic breast cancer patients based on size and deformability

Tozuka K - San Antonio Breast Cancer Symposium (SABCS) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Longitudinal analysis of circulating tumor cells and cell free tumor DNA by next generation sequencing in triple negative breast cancer

Howard K - San Antonio Breast Cancer Symposium (SABCS) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Triple-negative breast cancer

Cisplatin

p53 deficiency enhances metastatic potential of triple negative breast cancer by promoting growth in primary and metastatic sites

Powell E - San Antonio Breast Cancer Symposium (SABCS) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Triple-negative breast cancer

TP53

ARGX-111 depletes MET-expressing circulating tumor cells via enhanced ADCC, resulting in inhibition of metastasis

Morello V - San Antonio Breast Cancer Symposium (SABCS) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

ARGX-111

Circulating tumor cells count-based nomograms to predict survival of metastatic breast cancer patients: Results from the European pooled analysis

Bidard F-C - San Antonio Breast Cancer Symposium (SABCS) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Prognostic values of circulating tumor cell (CTC) enumeration and their clusters in advanced breast cancer

Ye Z - San Antonio Breast Cancer Symposium (SABCS) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Manual and digital detection of HER2 status of 2721 circulating tumour cells in patients with metastatic breast cancer

Brouwer A - San Antonio Breast Cancer Symposium (SABCS) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

CD44v as a potential predictive biomarker for pathologic complete response in primary HER2+ breast cancer: Utility of adaptive response biopsy in preoperative therapy

Yamauchi T - San Antonio Breast Cancer Symposium (SABCS) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Trastuzumab

Successful targeting HER2 in heavily pretreated HER2-negative metastatic breast cancer patients presenting with elevated serum levels of the HER2 extracellular domain and/or HER2 overexpressing circulating tumor cells

Kurbacher CM - San Antonio Breast Cancer Symposium (SABCS) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Trastuzumab

NRG-BR002: A phase IIR/III trial of standard of care therapy with or without stereotactic body radiotherapy (SBRT) &/or surgical ablation for newly oligometastatic breast cancer

Winter KA - San Antonio Breast Cancer Symposium (SABCS) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Quantification of circulating tumor cells using NanoFlares in breast cancer patients

Jain S - San Antonio Breast Cancer Symposium (SABCS) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

The predictive potential of metastatic serum markers and circulating tumor cells in advanced HER2-positive breast cancer patients - Focused on CNS metastases

Mikulova V - San Antonio Breast Cancer Symposium (SABCS) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Lapatinib reverses endocrine resistance in select patients with HER2 negative, hormone positive metastatic breast cancer

Sharma P - San Antonio Breast Cancer Symposium (SABCS) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Fulvestrant

VITAMIN D STATUS A TRANSVERSAL EVALUATION IN RHEUMATIC PATIENTS

J.L. Borges - European League Against Rheumatism (EULAR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Pulmonary arterial hypertension

Alkaline phosphatase

ULTRASOUND IN THE MANAGEMENT OF RHEUMATOID ARTHRITIS: RESULTS FROM THE RANDOMIZED CONTROLLED ARCTIC TRIAL

E.A. Haavardsholm - European League Against Rheumatism (EULAR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

N/A

German Hodgkin Study Group Phase I Trial Of Doxorubicin, Vinblastine, Dacarbazine, and Lenalidomide (AVD-Rev) For Older Hodgkin Lymphoma Patients

Boris Boll - American Society of Hematology (ASH) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Hodgkin's Lymphoma

Lenalidomide

Results Of a Phase I Study Of Clofarabine and 2 Gy Total Body Irradiation (TBI) As a Non-Myeloablative Preparative Regimen For Hematopoietic Stem Cell Transplantation (HSCT) In High Risk Children With Hematologic Malignancies: A Multi-Center TACL Study

Sandeep Soni - American Society of Hematology (ASH) , 2013

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Hematological malignancies

Mycophenolate mofetil

Early Versus Deferred Treatment With Combined Fludarabine, Cyclophosphamide and Rituximab (FCR) Improves Event-Free Survival In Patients With High-Risk Binet Stage A Chronic Lymphocytic Leukemia First Results Of a Randomized German-French Cooperative Phase III Trial

Carmen D Schweighofer - American Society of Hematology (ASH) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Chronic Lymphocytic Leukemia

Cyclophosphamide

Chemoimmunotherapy With Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Versus Bendamustine and Rituximab (BR) In Previously Untreated and Physically Fit Patients (pts) With Advanced Chronic Lymphocytic Leukemia (CLL): Results Of a Planned Interim Analysis Of The CLL10 Trial, An International, Randomized Study Of The German CLL Study Group (GCLLSG)

Barbara Eichhorst - American Society of Hematology (ASH) , 2013

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Chronic Lymphocytic Leukemia

Cyclophosphamide

Filters

1671 Abstracts